<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>135-CLONIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG2>
<DESCRIPTION>Described for desipramine, imipramine:

inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>135-CLONIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>135-CLONIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>135-CLONIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="YOHIMBINE" rxcui="220982">
<ATC code="G04BE04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
